Phase II Study of Pyrotinib in Combination With Fulvestrant in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive，Hormone Receptor（HR）-Positive Metastatic Breast Cancer
试验速览
- 阶段
- 2 期
- 入组人数
- 46
- 试验地点
- 2
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
HR+/HER2+（Human epidermal growth factor receptor 2 positive and hormone receptor positive）metastatic breast cancer is a special subtype of HER2+breast cancer. Conventional guidelines recommend chemotherapy combined with trastuzumab targeted therapy for this subtype of patients. However, the choice of treatment for these patients after treatment progress is a research hotspot in this field. Pyrotinib is a new class I small molecule Tyrosine kinase inhibitors（TKI） drug with high efficacy and low toxicity after the progress of trastuzumab therapy. Fulvestrant is the most preferred single-drug therapy for HR + metastatic breast cancer recommended unanimously by the guidelines, and fulvestrant and small molecule TKI have synergistic effects. Therefore, we envisage that fulvestrant combined with Pyrotinib in the treatment of HR+/HER2+ metastatic breast cancer in clinical practice has the advantages of improving efficacy and survival. To this end, we intend to conduct a prospective, multi-center, phase II clinical trial to evaluate the efficacy and safety of erlotinib in combination with fulvestrant in patients with human epidermal growth factor receptor 2 (HER2) positive，hormone receptor-positive metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Pathologically confirmed HER2 positive, hormone receptor-positive patients with locally advanced or metastatic breast cancer: HER2 IHC 3+, or HER2 IHC 2+ and FISH detection gene amplification, ER（estrogen receptor） and/or PR（progesterone receptor） Immunohistochemical staining of more than 10% tumor cells)
- •Aged ≥18 and ≤70 years.
- •ECOG（Eastern Cooperative Oncology Group） performance status of 0 to
- •The life expectancy of more than 12 weeks;
- •At least one measurable lesion exists(RECIST 1.1，Response Evaluation Criteria in Solid Tumors ), or only bone metastasis.
- •Previous neoadjuvant or adjuvant use of trastuzumab, but the disease-free interval between the end of the last trastuzumab and the progression of tumors was more than 12 months
- •Trastuzumab has not been treated in the past or only received first-line treatment for metastatic diseases.
- •It is required that previous (neo) adjuvant or endocrine therapy be given to patients, and that progress of the disease occur during or after treatment.
- •Patients with adequate organ function before enrollment:
- •Neutrophil granulocyte≥1.5×10^9/L Platelet≥100×10^9/L Hemoglobin≥90 g/L Signed informed consent.
排除标准
- •Patients who have not received trastuzumab, chemotherapy or endocrine therapy before;
- •Patients with visceral crisis;
- •Patients unable to swallow, with chronic diarrhea, intestinal obstruction, or multiple factors that affect drug use and absorption;
- •Patients with malignant serous effusion which cannot be controlled by drainage or other methods;
- •Less than 4 weeks from the last treatment in the last clinical trial;
- •Receiving any other antitumor therapy;
- •History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent;
- •Patients with serious heart disease;
- •Allergy to Pyrotinib; the history of immunodeficiency；
- •Known history of neurological or psychiatric disease, including epilepsy or dementia;
- •Patients during pregnancy or lactation, patients with childbearing potential tested positive in a baseline pregnancy test, or patients unwilling to take effective contraceptive measures throughout the trial;
- •Evidence of significant medical illness that will substantially increase the risk of the participation or completion of the study in the investigator's judgment. Examples included, but not limited to, hypertension, severe diabetes, etc;
- •Patients not eligible for this study judged by the investigator.
研究组 & 干预措施
Pyrotinib plus fulvestrant
Pyrotinib(400 mg once daily) + fulvestrant (500 mg, administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days)
干预措施: Pyrotinib combined with fulvestrant (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: Estimated 12 months
From enrollment to progression or death (for any reason)
次要结局
- Efficacy correlation biomarkers(Estimated 12 months)
- Clinical Benefit rate (CBR)(Estimated 12 months)
- Objective Response Rate (ORR)(Estimated 12 months)
- Overall Survival (OS)(Estimated 24 months)
- Adverse Events and Serious Adverse Events(From informed consent through 28 days following treatment completion)
- the quality of life(Estimated 24 months)
研究者
Ying Wang
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University